INmune Bio, Inc.

NASDAQ:INMB

Biotechnology

Healthcare
$1.89 +8.38%

+$0.15 today

Market cap
$50.25M
Beta
0.98
P/E (TTM)
-1.1
EPS (TTM)
-$1.56
52W Low $1.09High $3.24

Volume 0.09M

Average 0.68M

INMB Total Non-current Liabilities

All obligations due after more than one year.

INmune Bio, Inc.NASDAQ: INMB

Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total non-current liabilities rises 301.0% from a year ago

Total non-current liabilities stood at $806K at the end of Q1 FY2026, up 301.0% from a year earlier and up 96.1% from the prior quarter. Over 3 fiscal years it compounded at -66.3% a year.

Context

  • Total non-current liabilities amounted to 3.1% of total assets at the end of Q1 FY2026, up 2.6 pp from a year earlier.
  • Total non-current liabilities increased in 1 of the last 3 fiscal years.

What to watch

Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +301.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$806K+96.1% QoQ
Last fiscal yearDec 2025
$411K+68.4% YoY
Year agoMar 2025
$201K+301.0% since
Total Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+301.0%——
1 year+68.4%——
3-year CAGR-66.3%——
5-year CAGR——
10-year CAGR——

Total Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
411K USD
Year-over-year change
+68.4%
4-year CAGR
-59.6%

Total Non-current Liabilities vs competitors

How INMB compares with its peers on the latest reported figures

  • INMB's Mar 2026 total non-current liabilities of $806K is the 3rd highest of the 4 companies compared; the peer median is $10.62M.
  • Its year-over-year change of +301.0% is the highest of 4, against a peer median of -3.8%.
  • Total non-current liabilities amounts to 3.1% of total assets for INMB, versus a peer median of 28.9%.
INMB Competitors Peer median
Total Non-current Liabilities for INMB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
XFORX4 Pharmaceuticals, Inc.Mar 2026$78.06M -3.8%+9.8%28.9%
PDSBPDS Biotechnology CorporationMar 2026$10.62M +66.0%-20.3%43.1%
INMBINmune Bio, Inc.Mar 2026$806K +301.0%-66.3%3.1%
OKUROnKure Therapeutics, Inc.Mar 2026$12K -97.3%-94.3%0.0%
Peer median (excluding INMB) $10.62M-3.8%-20.3%28.9%

Competitors are the stored peer set for INMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents74.81M52.15M35.85M20.92M24.75M
Short-term Investments00000
Net Receivables5.5M8.46M2.44M1.41M4.54M
Inventory(5.5M)34K000
Other Current Assets5.5M(34K)1.51M331K595K
Total Current Assets82.61M64.68M39.94M22.66M29.89M
Property, Plant & Equipment (Net)726K507K414K307K914K
Goodwill00000
Intangible Assets16.51M16.51M16.51M16.51M0
Long-term Investments00000
Tax Assets00000
Other Non-current Assets99K99K131K79K1.55M
Total Non-current Assets17.34M17.12M17.06M16.9M2.46M
Total Assets99.95M81.8M57M39.56M32.35M
Account Payables3.8M5.21M7.9M6.56M7.79M
Short-term Debt72K5M9.92M00
Tax Payables00000
Deferred Revenue474K616K000
Other Current Liabilities(62K)9K524K517K0
Total Current Liabilities4.36M10.92M18.47M7.22M8.42M
Long-term Debt14.46M9.7M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities199K550K000
Total Non-current Liabilities15.36M10.77M397K244K411K
Total Liabilities19.72M21.69M18.86M7.47M8.83M
Common Stock18K18K817K22K27K
Retained Earnings(63.72M)(91.01M)(121.02M)(163.1M)(209.04M)
Accumulated OCI1K(699K)(799K)(575K)(737K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity80.23M60.1M38.14M32.1M23.52M
Total Debt15.23M15.31M10.44M384K1.03M
Net Debt(59.58M)(36.84M)(25.41M)(20.54M)(23.72M)

INmune Bio, Inc.

NASDAQ:INMB

Intrinsic Alpha fair value

Locked

Current Price

$1.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.